India · Delayed Price · Currency is INR Sun Pharmaceutical Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 saw 13.6% sales growth and strong gross margins, but EBITDA margin declined due to higher costs and lower milestone income. Innovative medicines and India business drove growth, while U.S. generics faced competition. Organon acquisition and new launches support future outlook.
-
The acquisition will create a top 25 global pharma company with a strong presence in women's health, biosimilars, and innovative medicines, leveraging Organon's global footprint and Sun's execution capabilities. The $11.75B deal is expected to deliver $350M in cost synergies and be EPS accretive from year one.
-
Q3 FY2026 saw 15.1% sales growth and improved margins, with strong performance in India and emerging markets, and continued investment in innovative medicines. US generics faced competition, but innovative launches and a robust cash position support future growth.
-
Q2 FY 2026 saw 8.6% sales growth, strong EBITDA margin, and robust innovative medicine expansion, with India and emerging markets outpacing broader industry growth. U.S. generics declined amid competition, while acquisitions and settlements impacted cash flows and intangibles.
-
Q1 FY 2026 saw 10.1% sales growth and 19.2% EBITDA growth, led by India and innovative medicines. U.S. business grew modestly, offset by generic pricing pressure, while new launches and acquisitions strengthened the specialty portfolio. Net cash remains robust at $3.1 billion.
Fiscal Year 2025
-
FY25 saw 9% sales growth and 17% EBITDA growth, led by India and specialty businesses, with Q4 margins improving. FY26 guidance is for mid to high single-digit growth, with $100 million earmarked for new specialty launches and R&D spend at 6%-8% of sales.
-
Q3 FY25 saw 10.5% sales growth and 15.3% EBITDA growth year-over-year, with strong India and specialty segment performance. Adjusted net profit rose 24.1%, and the company maintained a $3 billion net cash position while increasing its interim dividend.
-
Q2 FY25 saw 10.5% revenue growth and 28% net profit increase, driven by strong India and U.S. performance, higher specialty sales, and robust R&D investment. Guidance for FY25 R&D spend is 7%-8% of sales, with continued focus on specialty pipeline and new launches.
-
Q1 FY25 saw 6.3% revenue growth and 40.2% net profit rise year-over-year, with strong India and emerging market performance offsetting a slight U.S. sales decline. Specialty launches and Taro integration were key highlights, while litigation and pricing pressures remain risks.